|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mimura K, Yamada L, Ujiie D, Hayase S,
Tada T, Hanayama H, Thar Min AK, Shibata M, Momma T, Saze Z, et al:
Immunotherapy for esophageal squamous cell carcinoma: A review.
Fukushima J Med Sci. 64:46–53. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grivennikov SI, Greten FR and Karin M:
Immunity, inflammation, and cancer. Cell. 140:883–899. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Broz P and Monack DM: Molecular mechanisms
of inflammasome activation during microbial infections. Immunol
Rev. 243:174–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gross O, Thomas CJ, Guarda G and Tschopp
J: The inflammasome: An integrated view. Immunol Rev. 243:136–151.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fink SL and Cookson BT: Apoptosis,
pyroptosis, and necrosis: Mechanistic description of dead and dying
eukaryotic cells. Infect Immun. 73:1907–1916. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karki R, Man SM and Kanneganti TD:
Inflammasomes and cancer. Cancer Immunol Res. 5:94–99. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zitvogel L, Kepp O, Galluzzi L and Kroemer
G: Inflammasomes in carcinogenesis and anticancer immune responses.
Nat Immunol. 13:343–351. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okamoto M, Liu W, Luo Y, Tanaka A, Cai X,
Norris DA, Dinarello CA and Fujita M: Constitutively active
inflammasome in human melanoma cells mediating autoinflammation via
caspase-1 processing and secretion of interleukin-1beta. J Biol
Chem. 285:6477–6488. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Y, Kong H, Zeng X, Liu W, Wang Z, Yan
X, Wang H and Xie W: Activation of NLRP3 inflammasome enhances the
proliferation and migration of A549 lung cancer cells. Oncol Rep.
35:2053–2064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang H, Wang Y, Du Q, Lu P, Fan H, Lu J
and Hu R: Inflammasome-independent NLRP3 is required for
epithelial-mesenchymal transition in colon cancer cells. Exp Cell
Res. 342:184–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruchard M, Mignot G, Derangère V, Chalmin
F, Chevriaux A, Végran F, Boireau W, Simon B, Ryffel B, Connat JL,
et al: Chemotherapy-triggered cathepsin B release in
myeloid-derived suppressor cells activates the Nlrp3 inflammasome
and promotes tumor growth. Nat Med. 19:57–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wei Q, Mu K, Li T, Zhang Y, Yang Z, Jia X,
Zhao W, Huai W, Guo P and Han L: Deregulation of the NLRP3
inflammasome in hepatic parenchymal cells during liver cancer
progression. Lab Invest. 94:52–62. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen LC, Wang LJ, Tsang NM, Ojcius DM,
Chen CC, Ouyang CN, Hsueh C, Liang Y, Chang KP, Chen CC and Chang
YS: Tumour inflammasome-derived IL-1β recruits neutrophils and
improves local recurrence-free survival in EBV-induced
nasopharyngeal carcinoma. EMBO Mol Med. 4:1276–1293. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pirker R, Pereira JR, von Pawel J,
Krzakowski M, Ramlau R, Park K, de Marinis F, Eberhardt WE,
Paz-Ares L, Störkel S, et al: EGFR expression as a predictor of
survival for first-line chemotherapy plus cetuximab in patients
with advanced non-small-cell lung cancer: Analysis of data from the
phase 3 FLEX study. Lancet Oncol. 13:33–42. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guanen Q, Junjie S, Baolin W, Chaoyang W,
Yajuan Y, Jing L, Junpeng L, Gaili N, Zhongping W and Jun W:
miR-214 promotes cell metastasis and inhibits apoptosis of
esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling
pathway. Biomed Pharmacother. 105:350–361. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Martel C and Franceschi S: Infections
and cancer: Established associations and new hypotheses. Crit Rev
Oncol Hematol. 70:183–194. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He Q, Fu Y, Tian D and Yan W: The
contrasting roles of inflammasomes in cancer. Am J Cancer Res.
8:566–583. 2018.PubMed/NCBI
|
|
23
|
Moossavi M, Parsamanesh N, Bahrami A,
Atkin SL and Sahebkar A: Role of the NLRP3 inflammasome in cancer.
Mol Cancer. 17:1582018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Allen IC, TeKippe EM, Woodford RM, Uronis
JM, Holl EK, Rogers AB, Herfarth HH, Jobin C and Ting JP: The NLRP3
inflammasome functions as a negative regulator of tumorigenesis
during colitis-associated cancer. J Exp Med. 207:1045–1056. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang CF, Chen L, Li YC, Wu L, Yu GT,
Zhang WF and Sun ZJ: NLRP3 inflammasome activation promotes
inflammation-induced carcinogenesis in head and neck squamous cell
carcinoma. J Exp Clin Cancer Res. 36:1162017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li S, Liang X, Ma L, Shen L, Li T, Zheng
L, Sun A, Shang W, Chen C, Zhao W and Jia J: miR-22 sustains NLRP3
expression and attenuates H. pylori-induced gastric carcinogenesis.
Oncogene. 37:884–896. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mantovani A, Romero P, Palucka AK and
Marincola FM: Tumour immunity: Effector response to tumour and role
of the microenvironment. Lancet. 371:771–783. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Juliana C, Fernandes-Alnemri T, Kang S,
Farias A, Qin F and Alnemri ES: Non-transcriptional priming and
deubiquitination regulate NLRP3 inflammasome activation. J Biol
Chem. 287:36617–36622. 2012. View Article : Google Scholar : PubMed/NCBI
|
